Sort   by:  
 Page size 
ProteomicsElucidation of urinary extracellular vesicle protein signatures from patients with cribriform and intraductal prostate carcinoma
A comprehensive systemic assessment of the proteome changes that occur in prostate cancer (PCa) during the onset and course of the illness may produce results that are clinically significant. Proteins, the main participants in the majority of biological events, are both potential biomarkers and ther...
ORGANISM(S): Homo sapiens (Human) 
2025-05-06 | PXD043874 | Pride
Intraductal prostate carcinoma Proteomics Cribriform Liquid chromatography mass spectrometry Urinary extracellular vesicles 
GenomicsSpatial transcriptomics of intraductal carcinoma of the prostate (IDCP)
Spatial transcriptomics of intraductal carcinoma of the prostate (IDCP)
PRJNA1090950 | ENA
GenomicsMED12L Gene Alterations Define Aggressive BRCA2-Mutant Prostate Cancers
Germline mutation of BRCA2 increases the lifetime risk of developing prostate cancer (PCa) by over 700%. BRCA2-mutant PCa have poorer prognosis than sporadic PCa, with rapid development of metastatic, castrate-resistant prostate cancer (mCRPC) and 5-year cancer-specific survival rates of ~50-60%1-4....
EGAS00001001615 | EGA
UnknownThe expression of prostate-specific membrane antigen in intraductal carcinoma of the prostate.
Not available
S-EPMC12511330 | biostudies-literature
MetabolomicsContributions of the Microbiome-Derived Metabolome for Risk Assessment and Prognostication of Pancreatic Cancer

BACKGROUND Increasing evidence implicates microbiome involvement in the development and progression of pancreatic ductal adenocarcinoma (PDAC). Studies suggest that reflux of gut or oral microbiota can lead to colonization in the pancreas, resulting in dysbiosis that culminates ...

2023-08-09 | MTBLS7260 | MetaboLights
UnknownIntraductal Carcinoma of the Prostate as a Cause of Prostate Cancer Metastasis: A Molecular Portrait.
Not available
S-EPMC8834356 | biostudies-literature
UnknownAssessing the predictive value of intraductal carcinoma of the prostate (IDC-P) in determining abiraterone efficacy for metastatic hormone-sensitive prostate cancer (mHSPC) patients.
Not available
S-EPMC11648069 | biostudies-literature
UnknownIntraductal Carcinoma of the Prostate: To Grade or Not to Grade.
Not available
S-EPMC10669759 | biostudies-literature
UnknownThe heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Not available
S-EPMC9290811 | biostudies-literature
UnknownA Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer.
Not available
S-EPMC4988926 | biostudies-literature
Sort   by:  
 Page size